
Nectagen Inc Profile last edited on: 6/21/19
CAGE: 50UY9
UEI: KAFMLCY56WM3
Business Identifier: Next generation antibody: immunoglobulin-like scaffold: open access model Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 03
County: Wyandotte
Congr. District: 03
County: Wyandotte
Public Profile
Organized around development of next generation antibody: immunoglobulin-like scaffold, Nextagen is anchored in a very different business model from most for-profit firms, Established around the objective of advancing biomedical research by providing researchers with access to innovative technology and fostering a community for exchanging improvements, applications and data, the firm's management has created open technology platforms that biologists can customize and enhance for the community's benefit. Nectagen develops a critical mass of tools and reagents, supports users' development of new modifications and applications, and ensures open access to the technology for the academic community. Nectagen also has designed its platforms using components that are made available to non-profits on the condition that any modifications and derivatives made by the recipient are in turn made available to other non-profits and Nectagen
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2024 | 1 | NIH | $275,000 | |
Project Title: Development of Custom nanoCLAMP Affinity Chromatography Resins for Fast, Efficient Purification of Plasma Proteins | ||||
2023 | 1 | NIH | $274,500 | |
Project Title: Development of an Orally Available Therapeutic for Neutralizing C. difficile Toxin B | ||||
2021 | 1 | NIH | $252,484 | |
Project Title: Development of DNA-Labeled Antibody Mimetics as Low-Cost, High-Performance Reagents for Single Cell Analysis of Membrane Proteins | ||||
2019 | 1 | NIH | $150,000 | |
Project Title: Development of Enzyme Replacement Therapy for Complement C2-Deficiency | ||||
2018 | 1 | NIH | $150,000 | |
Project Title: Generation of High Resolution Antibody Mimetics to Improve the Visualization of Subcellular Structures by Super Resolution Microscopy |
Key People / Management
David M Chao -- Founder
Richard John Suderman -- Founder and Director of Research
Shane Gibson -- Lab Tech
Daren A Rice -- Lab Tech
Eric J Strick -- Lab Tech
Richard John Suderman -- Founder and Director of Research
Shane Gibson -- Lab Tech
Daren A Rice -- Lab Tech
Eric J Strick -- Lab Tech
Company News
There are no news available.